Advertisement
Home Blog Page 3485
Vonvendi has been approved by the U.S. Food and Drug Administration to treat adults with von Willebrand disease.

FDA Approves Vonvendi to Treat von Willebrand Disease

0
Approved for the as-needed treatment and control of bleeding episodes in adults
Kanuma (sebelipase alfa) has been approved by the U.S. Food and Drug Administration as the first treatment for LAL deficiency (Wolman disease or cholesteryl ester storage disease).

FDA Approves Kanuma for Lysosomal Acid Lipase Deficiency

0
For treatment of LAL deficiency, also known as Wolman disease or cholesteryl ester storage disease
Fewer American families are struggling to pay medical bills

CDC: Fewer Americans Struggling With Medical Bills

0
U.S. report shows 12 million are no longer in families having trouble paying for health care
Children of mothers with polycystic ovary syndrome may have an increased risk for autism spectrum disorders

Maternal PCOS May Raise Odds for Autism in Offspring

0
Odds of ASD further increased among mothers with both PCOS and obesity
The combination of effective transmission of knowledge

Med Ed Can Be Improved for High-Value, Cost-Conscious Care

0
Review shows knowledge transmission, reflective practice, supportive environment aid learning
Cannabidiol might benefit some children with epilepsy whose seizures aren't controlled by approved medications

Cannabidiol Shows Promise in Pediatric Epilepsy

0
Preliminary studies link cannabidiol to seizure reduction, but drug interactions remain a concern
Compared to their international peers

Survey: U.S. PCPs Feel Ill-Prepared for Complex Care

0
For example, fewer than half feel they're prepared to manage dementia patients
Androgen deprivation therapy for prostate cancer might dramatically increase a man's risk of developing Alzheimer's disease

ADT for Prostate CA Tied to Increased Alzheimer’s Risk

0
Research suggests dose-dependent effect
The rate of vaso-occlusive crisis events is not significantly lower for children and adolescents with sickle-cell anemia receiving prasugrel versus placebo

ASH: Prasugrel Doesn’t Cut Vaso-Occlusive Crisis in Sickle Cell

0
Rate of vaso-occlusive crisis events is not lower for children receiving prasugrel versus placebo
Oral venetoclax and acalabrutinib are active in patients with relapsed or refractory chronic lymphocytic leukemia

ASH: Venetoclax, Acalabrutinib Active in Relapsed CLL

0
Two studies show beneficial effects for patients with relapsed chronic lymphocytic leukemia